LIFECORE BIOMEDICAL, INC. Impairment of Long-Lived Assets to be Disposed of
LIFECORE BIOMEDICAL, INC. (LFCR) reported Impairment of Long-Lived Assets to be Disposed of of $0 for the 12-month period ending 2022-05-29, per its 10-K filed 2024-03-20.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf · last filed 2024-03-20
- LIFECORE BIOMEDICAL, INC. impairment of long-lived assets to be disposed of for the quarter ending 2021-05-30 was $500.00K.
- LIFECORE BIOMEDICAL, INC. impairment of long-lived assets to be disposed of for fiscal 2022 was $0.00.
- LIFECORE BIOMEDICAL, INC. impairment of long-lived assets to be disposed of for fiscal 2020 was $10.90M.
| Period end | Impairment of Long-Lived Assets to be Disposed of 3 month | Impairment of Long-Lived Assets to be Disposed of 6 month | Impairment of Long-Lived Assets to be Disposed of 12 month |
|---|---|---|---|
| 2022-05-29 | $0.00 10-K · filed 2024-03-20 | ||
| 2021-05-30 | $500.00K 10-K · filed 2021-07-29 | ||
| 2020-05-31 | $10.90M 10-K · filed 2020-08-14 | ||
| 2019-11-24 | $400.00K 10-Q · filed 2020-01-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |